Proqr Therapeutics (PRQR) Stock Price, Quote & News

Company Profile

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 88 166 7000

Website: www.proqr.com

Address:

Zernikedreef 9, Leiden, Netherlands

FutureInvesting777 Sep. 11 at 4:42 PM

$PRQR well it’s possible that we see 1.6 - 1.70 again soon.

1 · Reply

LoveRetailFroth Sep. 10 at 2:58 PM

$PRQR Good Morning ☕️ Added another 20k. 60k 💪 Long here

1 · Reply

Akex1987ita Sep. 9 at 9:21 PM

$PRQR Today Cantor event highlights: AX-0811 dosing has started, with PD data from the first 2 cohorts expected in early Jan. Management projects 40–65% editing and will define biomarker thresholds on Sept 30. AX-0810 9mg + 12-week follow-up will be presented later this year. 810/811 selection will drive the BA IIT, with H1’27 data. Potential pivotal Phase 2 targeted for mid-2027. 5 clinical readouts across 4 molecules over the next 12 months. My opinion: good progress, but the real test is still ahead. Until AX-0811 proves in humans the major increase in editing predicted vs AX-0810, the platform’s true potential remains unproven.

1 · Reply

FutureInvesting777 Sep. 9 at 7:43 PM

$PRQR well well well back to 1.7-1.8 seems like it. They are determined to take it back down for the time being.

0 · Reply

johnnygogogo Sep. 9 at 6:44 PM

$PRQR 4,439 watchers and not one of us can pierce the corporate veil at LLY… also, I hope Hodor and the traders who don’t have a clue what this is all set stop losses at the super obvious $2 mark…

1 · Reply

Valueforall Sep. 9 at 2:53 PM

$PRQR FYI and this might be garbage 🗑️ talk but this ticker came up in 2 district LLM models trained with bio data 📊 that could have the best possibility with least risk to 5x in the next 6 months. Of these 2 models no other 2 tickers overlapped. Just this one.

2 · Reply

LoveRetailFroth Sep. 9 at 1:05 PM

$SMMT Good Morning my bio 💎s☕️ $AMLX $RXRX $PRQR

0 · Reply

Akex1987ita Sep. 9 at 12:42 PM

$PRQR ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811. https://www.proqr.com/press-releases/proqr-announces-first-participant-dosed-in-phase-1-study-of-ax-0811-and-virtual-investor-and-analyst-educational-event-on-september-30-2026

1 · Reply

FutureInvesting777 Sep. 8 at 4:17 PM

$PRQR wonder how the invester meeting going today!!

0 · Reply

johnnygogogo Sep. 8 at 3:29 PM

$WVE $PRQR $KRRO if the underwriters / MMs want to successfully sell an ADARx ipo, they’re going to have to lift the valuations of these three, otherwise investors won’t buy what they’re selling at the valuation they want and instead buy the discount on the already established and already public

0 · Reply

ProQR Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

2026-09-09T12:15:25.000Z - 3 days ago

ProQR Therapeutics doses first participant in AX-0811 clinical trial

Sep 9, 2026, 8:00 AM EDT - 3 days ago

ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026

Sep 2, 2026, 8:00 AM EDT - 10 days ago

ProQR to Participate in Upcoming Investor Conferences in September 2026

2026-08-20T11:45:10.000Z - 23 days ago

ProQR Therapeutics initiated with a Buy at BofA

Aug 13, 2026, 7:00 AM EDT - 4 weeks ago

ProQR Announces Second Quarter 2026 Operating and Financial Results

Aug 13, 2026, 7:00 AM EDT - 4 weeks ago

ProQR Therapeutics Earnings release: Q2 2026

2026-07-06T20:15:23.000Z - 2 months ago

ProQR Therapeutics registers to sell 3.03M ordinary shares for holders

Jul 6, 2026, 8:00 AM EDT - 2 months ago

ProQR Therapeutics Registration statement: Registration filing

2026-06-26T11:35:19.000Z - 2 months ago

ProQR Therapeutics price target lowered to $10 from $14 at Raymond James

2026-06-26T08:40:08.000Z - 2 months ago

ProQR Therapeutics price target lowered to $10 from $11 at JonesResearch

2026-06-26T00:55:07.000Z - 2 months ago

ProQR Therapeutics price target lowered to $3 from $4 at Chardan

Jun 25, 2026, 7:00 AM EDT - 2 months ago

ProQR Therapeutics Slides: Conference presentation

2026-06-25T10:40:22.000Z - 2 months ago

ProQR Therapeutics prices 27.62M shares at $1.81 in registered direct offering

LLY

2026-06-25T10:35:33.000Z - 2 months ago

ProQR Therapeutics announces positive Phase 1 data for AX-0810

Jun 25, 2026, 6:35 AM EDT - 2 months ago

ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement

Jun 25, 2026, 6:25 AM EDT - 2 months ago

ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform

May 12, 2026, 7:00 AM EDT - 4 months ago

ProQR Announces First Quarter 2026 Operating and Financial Results

May 12, 2026, 7:00 AM EDT - 4 months ago

ProQR Therapeutics Earnings release: Q1 2026

May 11, 2026, 8:00 AM EDT - 4 months ago

ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform

May 4, 2026, 8:00 AM EDT - 4 months ago

ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026

Apr 30, 2026, 8:00 AM EDT - 4 months ago

ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors

2026-04-08T20:45:41.000Z - 5 months ago

ProQR Therapeutics management to meet with Cantor Fitzgerald

2026-04-08T20:40:37.000Z - 5 months ago

ProQR Therapeutics management to meet with Oppenheimer

Apr 8, 2026, 4:00 PM EDT - 5 months ago

ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event

Apr 8, 2026, 10:00 AM EDT - 5 months ago

ProQR Therapeutics Transcript: Status update

Apr 8, 2026, 10:00 AM EDT - 5 months ago

ProQR Therapeutics Press release: Status update

Apr 8, 2026, 10:00 AM EDT - 5 months ago

ProQR Therapeutics Slides: Status update

Apr 8, 2026, 8:00 AM EDT - 5 months ago

ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board

Mar 25, 2026, 8:00 AM EDT - 5 months ago

ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026

2026-03-12T11:46:03.000Z - 6 months ago

ProQR Therapeutics assumed with an Outperform at Oppenheimer

2026-03-12T11:10:29.000Z - 6 months ago

ProQR Therapeutics reports FY25 EPS (EUR 0.40) vs (EUR 0.32) last year

Mar 12, 2026, 7:00 AM EDT - 6 months ago

ProQR Announces Year End 2025 Operating and Financial Results

Mar 12, 2026, 7:00 AM EDT - 6 months ago

ProQR Therapeutics Annual report: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 6 months ago

ProQR Therapeutics Earnings release: Q4 2025

Mar 11, 2026, 3:25 PM EDT - 6 months ago

ProQR Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Mar 3, 2026, 4:30 PM EST - 6 months ago

ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference

2026-02-19T15:50:54.000Z - 6 months ago

ProQR Therapeutics participates in a conf call hosted by Cantor Fitzgerald

2026-02-09T13:05:14.000Z - 7 months ago

ProQR Therapeutics directors Dinko Valerio, Alison Lawton to depart

Feb 9, 2026, 8:00 AM EST - 7 months ago

ProQR Announces Planned Changes to Board Composition

2026-01-08T13:15:17.000Z - 8 months ago

ProQR announces initial safety, PK data from Phase 1 trial of AX-0810

LLY

Jan 8, 2026, 8:00 AM EST - 8 months ago

ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook

Dec 4, 2025, 8:20 AM EST - 9 months ago

ProQR Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 1, 2025, 8:00 AM EST - 9 months ago

ProQR to Participate in 8th Annual Evercore Healthcare Conference

Nov 6, 2025, 9:30 AM EST - 10 months ago

ProQR Therapeutics Earnings release: Q3 2025

2025-11-06T12:21:19.000Z - 10 months ago

ProQR Therapeutics reports Q3 (EUR 0.10) vs (EUR 0.10) last year

Nov 6, 2025, 7:00 AM EST - 10 months ago

ProQR Announces Third Quarter 2025 Operating and Financial Results

Nov 3, 2025, 10:00 AM EST - 10 months ago

ProQR Therapeutics Transcript: Study Update

Nov 3, 2025, 10:00 AM EST - 10 months ago

ProQR Therapeutics Press release: Study Update

Nov 3, 2025, 10:00 AM EST - 10 months ago

ProQR Therapeutics Slides: Study Update

Oct 21, 2025, 1:00 PM EDT - 10 months ago

ProQR Therapeutics Transcript: Chardan’s 9th Annual Genetic Medicines Conference

2025-10-20T12:05:08.000Z - 10 months ago

ProQR Therapeutics receives CTA authorization for AX-0810

Oct 20, 2025, 8:00 AM EDT - 10 months ago

ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025

2025-10-16T16:15:25.000Z - 11 months ago

ProQR Therapeutics management to meet with Citizens JMP

Oct 13, 2025, 8:30 AM EDT - 11 months ago

ProQR to Participate in Upcoming Investor Conferences in October 2025

Aug 7, 2025, 9:30 AM EDT - 1 year ago

ProQR Therapeutics Earnings release: Q2 2025

2025-08-07T11:32:48.000Z - 1 year ago

ProQR Therapeutics reports Q2 EPS (EUR 0.21) vs. (EUR 0.13) last year

Aug 7, 2025, 7:00 AM EDT - 1 year ago

ProQR Announces Second Quarter 2025 Operating and Financial Results

Jul 28, 2025, 8:00 AM EDT - 1 year ago

ProQR Announces Upcoming Presentation at RNA Editing Summit

Jun 26, 2025, 4:30 PM EDT - 1 year ago

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

May 12, 2025, 8:00 AM EDT - 1 year ago

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

May 8, 2025, 11:30 AM EDT - 1 year ago

ProQR Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

ProQR Announces First Quarter 2025 Operating and Financial Results

May 7, 2025, 6:00 PM EDT - 1 year ago

ProQR Therapeutics Earnings release: Q1 2025

May 2, 2025, 8:00 AM EDT - 1 year ago

ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference

May 1, 2025, 8:00 AM EDT - 1 year ago

ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025

Apr 14, 2025, 7:00 AM EDT - 1 year ago

ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

Mar 13, 2025, 1:30 PM EDT - 1 year ago

ProQR Therapeutics Annual report: Q4 2024

Mar 13, 2025, 1:30 PM EDT - 1 year ago

ProQR Therapeutics Press release: Q4 2024

Mar 13, 2025, 8:00 AM EDT - 1 year ago

ProQR Therapeutics Registration statement: Registration Filing

Mar 13, 2025, 7:00 AM EDT - 1 year ago

ProQR Announces Year End 2024 Operating and Financial Results

Dec 11, 2024, 10:00 AM EST - 1 year ago

ProQR Therapeutics Transcript: AGM 2024

Dec 10, 2024, 8:00 AM EST - 1 year ago

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

Nov 7, 2024, 9:30 AM EST - 1 year ago

ProQR Therapeutics Earnings release: Q3 2024

Oct 25, 2024, 4:45 PM EDT - 1 year ago

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

Oct 22, 2024, 10:15 PM EDT - 1 year ago

ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement

Oct 22, 2024, 4:01 PM EDT - 1 year ago

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

Oct 7, 2024, 8:00 AM EDT - 1 year ago

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society

Sep 30, 2024, 8:00 AM EDT - 1 year ago

ProQR Therapeutics Registration statement: Registration Filing

Sep 17, 2024, 9:10 AM EDT - 1 year ago

ProQR Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 10, 2024, 4:30 PM EDT - 2 years ago

ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference

Aug 8, 2024, 7:21 AM EDT - 2 years ago

ProQR Therapeutics Earnings release: Q2 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

ProQR Therapeutics Transcript: Status Update

May 9, 2024, 8:00 AM EDT - 2 years ago

ProQR Therapeutics Press release: Status Update

May 9, 2024, 8:00 AM EDT - 2 years ago

ProQR Therapeutics Slides: Status Update

May 9, 2024, 7:00 AM EDT - 2 years ago

ProQR Announces First Quarter 2024 Operating and Financial Results

May 9, 2024, 2:00 AM EDT - 2 years ago

ProQR Therapeutics Earnings release: Q1 2024

Apr 23, 2024, 7:00 AM EDT - 2 years ago

ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024

Apr 22, 2024, 4:31 PM EDT - 2 years ago

ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting

Apr 19, 2024, 7:00 AM EDT - 2 years ago

ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

Mar 13, 2024, 7:00 AM EDT - 2 years ago

ProQR Announces Year End 2023 Operating and Financial Results

Mar 13, 2024, 6:00 AM EDT - 2 years ago

ProQR Therapeutics Annual report: Q4 2023

Mar 13, 2024, 6:00 AM EDT - 2 years ago

ProQR Therapeutics Earnings release: Q4 2023

Jan 19, 2024, 7:00 AM EST - 2 years ago

ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

Jan 5, 2024, 7:00 AM EST - 2 years ago

ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration

Dec 8, 2023, 7:30 AM EST - 2 years ago

ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

Nov 7, 2023, 7:00 AM EST - 2 years ago

ProQR Announces Third Quarter 2023 Operating and Financial Results

Nov 7, 2023, 5:00 AM EST - 2 years ago

ProQR Therapeutics Earnings release: Q3 2023

Nov 6, 2023, 7:00 AM EST - 2 years ago

ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

Sep 28, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

Sep 7, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference

Aug 3, 2023, 7:00 AM EDT - 3 years ago

ProQR Announces Second Quarter 2023 Operating and Financial Results

Aug 3, 2023, 5:00 AM EDT - 3 years ago

ProQR Therapeutics Earnings release: Q2 2023

Aug 1, 2023, 7:00 AM EDT - 3 years ago

ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR's Sepofarsen and Ultevursen Ophthalmic Assets

Jul 6, 2023, 7:00 AM EDT - 3 years ago

ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit

FutureInvesting777 Sep. 11 at 4:42 PM

$PRQR well it’s possible that we see 1.6 - 1.70 again soon.

1 · Reply

LoveRetailFroth Sep. 10 at 2:58 PM

$PRQR Good Morning ☕️ Added another 20k. 60k 💪 Long here

1 · Reply

Akex1987ita Sep. 9 at 9:21 PM

1 · Reply

FutureInvesting777 Sep. 9 at 7:43 PM

$PRQR well well well back to 1.7-1.8 seems like it. They are determined to take it back down for the time being.

0 · Reply

johnnygogogo Sep. 9 at 6:44 PM

1 · Reply

Valueforall Sep. 9 at 2:53 PM

2 · Reply

LoveRetailFroth Sep. 9 at 1:05 PM

$SMMT Good Morning my bio 💎s☕️ $AMLX $RXRX $PRQR

0 · Reply

Akex1987ita Sep. 9 at 12:42 PM

1 · Reply

FutureInvesting777 Sep. 8 at 4:17 PM

$PRQR wonder how the invester meeting going today!!

0 · Reply

johnnygogogo Sep. 8 at 3:29 PM

0 · Reply

Akex1987ita Sep. 7 at 2:40 PM

Update to my previous post: $PRQR AX-0811 has progressed beyond CTA approval. CTIS now shows the trial as ongoing/recruiting, with trial and recruitment start on Aug 26. SGS Belgium is actively recruiting for ProQR study 2600030, with Cohort 2 already scheduled for October. Cohort 1 is no longer publicly listed. First dosing is not yet confirmed, but execution is clearly underway.

1 · Reply

Akex1987ita Sep. 7 at 2:07 PM

$PRQR: AX-0811 is now listed in EU CTIS as Phase 1 trial 2026-526764-21-00 / PQ-0811-101, sponsor ProQR Therapeutics VIII B.V., in healthy volunteers in Belgium. Status: “Authorised, recruitment pending”; decision date 25 Aug 2026. Target enrollment: 44 participants. This indicates the CTA hurdle has been cleared. Next key signal: recruitment start / first participant dosed. Strong execution checkpoint for Axiomer!

0 · Reply

Filvul Sep. 3 at 1:14 PM

$PRQR

0 · Reply

FutureInvesting777 Sep. 2 at 1:12 PM

$PRQR https://www.proqr.com/press-releases/proqr-to-participate-in-upcoming-investor-conferences-in-september-2026

1 · Reply

FutureInvesting777 Sep. 2 at 11:21 AM

$PRQR they do it every time like clock works because they can; good to those who capitalize…..

0 · Reply

Filvul Sep. 1 at 2:24 PM

$PRQR Do you guys know when we could expect some news, good or bad?!

2 · Reply

topstockalerts Sep. 1 at 11:07 AM

Pre Market Top Gainers PT2 $YFOR $FRVO $GYGY $DWTX $PRQR

0 · Reply

dirkfrank Aug. 31 at 8:43 PM

$PRQR keep on dreaming $10 $20 $40 etc.

2 · Reply

Filvul Aug. 31 at 2:17 PM

$PRQR damn...

1 · Reply

Market_Max Aug. 28 at 2:01 PM

$PRQR Now I get why the company has been effectively quiet since $LLY got into the picture. $LLY is now hiding all their phase 1 trials and MoA to protect intellectual property, especially with the current spate of Chinese biotech copying... it's gotten that bad. We are effectively an Eli Lilly early stage subsidiary !

1 · Reply

ehpats Aug. 27 at 2:25 PM

$PRQR I think we have some groups of traders that are trying to swing this for small profits. Not a bad move with no news expected for months.

1 · Reply

Akex1987ita Aug. 27 at 1:40 PM

in my opinion November could be a key $PRQR catalyst. AASLD’s Liver Meeting (Nov 5–9) looks like a strong candidate for the full AX-0810 Phase 1 dataset, including 9 mg/kg + 12-week follow-up. Its Sep 15–25 late-breaking window fits Cohort 3 timing remarkably well.

0 · Reply

Market Cap	195.98M
Revenue (ttm)	18.00M
Net Income (ttm)	-47.73M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-265.17%
Debt to Equity Ratio	0.06

Volume	581,200
Avg Vol	932,572
Day's Range	N/A - N/A
Shares Out	105.36M
Stochastic %K	2%
Beta	0.06
Analysts	Strong Sell
Price Target	$8.22